Teva Pharmaceutical Industries Ltd. has gotten some breathing room with news that the launch of a generic rival to the important 40mg version of its blockbuster multiple sclerosis drug Copaxone (glatiramer) has been delayed due to a manufacturing issue.
Teva Catches A Break On Copaxone 40mg, But For How Long?
An FDA warning letter cites deficiencies at the Pfizer-owned manufacturing facility poised to produce a Momenta/Sandoz generic competitor. It’s unclear how long Pfizer might take to resolve the violations, which include particulates in finished products.